Here are the key populations to keep an eye on for potential HCV infection in EU/EEA countries


  • Antara Ghosh
  • Medical news
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Infection with hepatitis C (HCV) or hepatitis B virus (HBV) is a significant cause of liver disease-related morbidity and mortality in the European Union/European Economic Area (EU/EEA). With advent of direct-acting antivirals (cure rates >90%), elimination of chronic viral hepatitis is a possibility. An effective elimination strategy requires identification of patients at high risk for infection. A systematic review published in journal BMC Infectious Disease, provides estimates of HBV/HCV prevalence in EU/EAA among 3 high-risk groups: men who have sex with men (MSM), people who inject drugs (PWID) and people in prison.

Sixty-eight HBV/HCV prevalence estimates from 23 EU/EEA countries were evaluated. Among MSM, HBV prevalence estimates ranged from 0.0%-0.1% in Estonia and the UK to 1.4% in France. HCV estimates ranged between 4.7%-1.8%, 2.5%-2.9%, 0.7%-1.3% and 2.2%-1.6% for Estonia, Croatia, the Netherlands and the UK, respectively. HBV prevalence in the prison population ranged from 10% for Croatia, France, Germany and Hungary to >80% for Luxembourg. HBV prevalence in PWID ranged from 0.5% in Croatia, Hungary and Ireland, to >6% in Hungary and Portugal while HCV prevalence ranged between ≥30% and ≥50%.

Overall, HBV prevalence was highest among people in prison (range, 0.3%-25.2%) followed by PWID (0.5%-6.1%) and MSM (0.0%-1.4%). The highest prevalence of HCV was also found among people in prison (4.3%-86.3%) and PWID (13.8%-84.3%) followed by MSM (0.0%-4.7%).

Authors commented: “PWID and the prison population should be prioritised as the key populations for HBV/HCV screening and treatment.” They further added, “Our data does not support MSM as a high-risk group for chronic hepatitis B infection but it should still be considered as a key population for targeted action.”

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit